| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TLCD1 |
| Uniprot No | Q96CP7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-247aa |
| 氨基酸序列 | RADPLRTWRWHNLLVSFAHSIVSGIWALLCVWQTPDMLVEIETAWSLSGYLLVCFSAGYFIHDTVDIVASGQTRASWEYLVHHVMAMGAFFSGIFWSSFVGGGVLTLLVEVSNIFLTIRMMMKISNAQDHLLYRVNKYVNLVMYFLFRLAPQAYLTHFFLRYVNQRTLGTFLLGILLMLDVMIIIYFSRLLRSDFCPEHVPKKQHKDKFLTE |
| 预测分子量 | 26.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TLCD1重组蛋白的3篇模拟参考文献及其摘要概括(注：以下文献信息为假设示例，实际引用需核实真实来源)：
---
1. **文献名称**: *"TLCD1 regulates membrane lipid composition and cellular signaling in cancer cells"*
**作者**: Smith A, et al. (2015)
**摘要**: 本研究通过重组TLCD1蛋白，揭示了其在调控癌细胞膜磷脂组成中的作用。实验表明，TLCD1通过影响脂肪酸链长度改变膜流动性，进而调节EGFR等膜受体信号通路活性。
2. **文献名称**: *"Structural insights into the enzymatic mechanism of TLCD1 in lipid remodeling"*
**作者**: Johnson R, et al. (2020)
**摘要**: 作者利用重组TLCD1蛋白进行晶体结构解析，发现其通过保守的酶活性中心催化溶血磷脂酸的重酰化反应，突变实验证实关键氨基酸对脂质代谢功能至关重要。
3. **文献名称**: *"TLCD1 deficiency alters hepatic lipid metabolism in a mouse model"*
**作者**: Brown K, et al. (2019)
**摘要**: 研究通过重组TLCD1蛋白回补实验，证明TLCD1敲除小鼠肝脏中甘油三酯累积异常，TLCD1通过维持磷脂酰胆碱稳态参与非酒精性脂肪肝的发展。
---
**提示**：以上文献为模拟内容，实际研究中请通过PubMed或Google Scholar以关键词“TLCD1 recombinant protein”“TLCD1 lipid metabolism”等检索真实文献。
TLCD1 (TLC domain-containing protein 1) is a member of the TLC (TRAM-LAG1-CLN8) domain protein family, which is evolutionarily conserved and implicated in lipid metabolism and membrane dynamics. The human TLCD1 gene, located on chromosome 17q21.31. encodes a 291-amino-acid protein containing a central TLC domain. This domain is structurally homologous to those found in proteins like CERT (ceramide transfer protein) and FAPP2 (phosphatidylinositol-4-phosphate adaptor protein 2), suggesting potential roles in lipid transport or modification. TLCD1 is ubiquitously expressed, with higher levels observed in tissues such as the liver, brain, and kidneys, and is localized to the endoplasmic reticulum (ER) and Golgi apparatus.
Recombinant TLCD1 protein is typically produced using heterologous expression systems (e.g., Escherichia coli, mammalian cell lines) to study its biochemical properties and cellular functions. Purification often involves affinity tags (e.g., His-tag, GST-tag) followed by chromatography. Studies indicate TLCD1 may regulate phosphatidylcholine (PC) metabolism by modulating fatty acid incorporation into phospholipids, potentially influencing membrane composition and fluidity. It has been linked to cellular stress responses, with altered expression observed in metabolic disorders and cancers. For instance, TLCD1 knockdown reduces cancer cell proliferation, suggesting its involvement in tumorigenesis.
Despite progress, TLCD1's precise molecular mechanisms remain unclear. Current research focuses on its interactions with lipid biosynthetic enzymes, membrane contact sites, and roles in lipid homeostasis. Recombinant TLCD1 serves as a critical tool for structural studies, enzymatic assays, and antibody development, aiding investigations into its pathophysiological relevance and therapeutic potential in lipid-related diseases.
×
